Williams, Anna Maria
MetadataShow full item record
Metallic anticancer compounds have generated increasing amounts of interest since the discovery of cisplatin. The chemical properties of ruthenium make it an ideal candidate for such studies. Organometallic Ru-arene complexes are attractive for both primary tumor and antimetastatic treatments; in particular, [(η6-arene)Ru(XY)(Z)] complexes and RAPTA complexes have been studied intensely. Ligand variability of these compounds allows for detailed study of their structure-activity relationships, creating a valuable knowledge base for the educated design of ideal Ru anticancer complexes. In addition, a variety of different methods have been developed to mediate Ru compounds activity, to include the addition of targeting moieties and the development of Ru photodynamic therapeutic agents. The rate at which these compounds are being researched is currently increasingly, suggesting the possibility of their clinical use in the near future.